Opioid-free anesthesia (OFA) is noninferior to opioid-sparing anesthesia (OSA) for managing pain after laparoscopic cholecystectomy, and it leads to faster bowel recovery. In a randomized controlled trial with 81 adults, pain scores over 36 hours were similar between groups (area under the curve 7.3 for OFA vs. 6.9 for OSA; the difference was 0.384, below the noninferiority threshold of 1.0). Although early pain in the first 12 hours after PACU discharge was slightly higher with OFA, overall pain control was sufficient in both groups. Bowel recovery occurred sooner with OFA (13.8 vs. 15.5 hours). Other outcomes, including hemodynamics and patient satisfaction, were comparable.
Ofatumumab, a fully humanized anti-CD20 antibody, reduced disease activity and disability progression in Chinese patients with relapsing multiple sclerosis. Among 38 treatment-naïve patients, the annualized relapse rate fell from 0.27 to 0.05, and the median disability score dropped from 2.50 to 2.00 after 12 months. Among 59 patients who switched from oral therapies (teriflunomide, siponimod, fingolimod, dimethyl fumarate) due to disease progression, relapse, or MRI activity, the relapse rate decreased from 0.45 to 0.08 and disability scores improved from 2.00 to 1.00. No new MRI lesions, relapses, or serious adverse events occurred in either group.
An 8-week Mindfulness-Based Cognitive Therapy (MBCT) intervention reduced stigma and self-harm, and improved mindfulness and insight in young women with schizophrenia. In a randomized trial of 62 female patients, those receiving MBCT showed significantly lower scores on measures of stigma and self-harm compared to a control group receiving conventional treatment. Mindfulness scores and treatment attitudes improved significantly. Higher mindfulness was linked to lower stigma. The findings suggest MBCT can lessen the cumulative burden of mental disorders and self-harm in this population.